Click here to close now.




















Welcome!

News Feed Item

Molecular Medicine Awards 2nd Annual Ross Prize to NIH Scientist Dr. John O'Shea

Celebration and symposium to be held in New York on June 9

MANHASSET, N.Y., April 23, 2014 /PRNewswire-USNewswire/ -- The Feinstein Institute for Medical Research today announced that John J. O'Shea, MD, scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health (NIH), will be the recipient of the second annual Ross Prize in Molecular Medicine. The Ross Prize is issued via the Feinstein Institute's peer-reviewed, open-access journal, Molecular Medicine. The Prize, which includes a $50,000 gift, will be formally presented to Dr. O'Shea on June 9 at the New York Academy of Sciences in Manhattan, followed by an academic lecture by Dr. O'Shea and several other preeminent researchers.

The Ross Prize is made possible by the generosity of Feinstein Institute board members Robin and Jack Ross of Upper Brookville, NY. It is awarded annually by Molecular Medicine to mid-career scientists who have made a demonstrable impact in the understanding of human diseases pathogenesis and/or treatment, and who hold significant promise for making even greater contributions to the general field of molecular medicine.

"John O'Shea turned his passion for clinical care into a successful research career pushing the frontiers of molecular medicine," said Feinstein Institute President, Kevin J. Tracey, MD, who also serves as editor-in-chief of Molecular Medicine. "His dedication and focus on the cytokine field have led to new treatments for immune diseases."

"It is very humbling to be awarded the 2014 Ross Prize in Molecular Medicine," said Dr. O'Shea. "From the beginning of my career, I was hoping to make discoveries that are important scientifically, but also directly help people – for me, it doesn't really get any better than that. It is very gratifying that my efforts to these ends are being recognized by this award."

On June 9, at a ceremony to be held at the New York Academy of Sciences in Manhattan, Dr. O'Shea will be presented the Ross Prize. After the award presentation, Dr. O'Shea; James P. Allison, PhD, The University of Texas MD Anderson Cancer Center; Louis M. Staudt, MD, PhD, National Cancer Institute, NIH; and Charles A. Dinarello, MD, University of Colorado at Denver, will each present scientific lectures. These preeminent researchers will discuss the mechanisms of immune system function and signaling, which may improve the treatment for cancer and various autoimmune diseases. To learn more about and register for the Ross Prize celebration and symposium, visit www.nyas.org/RossPrize2014. Registration is free.

Dr. O'Shea has been a physician and immunologist at NIH for 33 years. He has made fundamental discoveries related to the signaling of cytokines – molecules that are critical for the development and functioning of the immune system. His research also has focused on the molecular cause of primary immunodeficiencies, inherited conditions in which immune function is impaired, and the genetic basis of autoinflammatory disorders, conditions in which the body attacks its own tissues. He was awarded a US patent for his work on Janus family kinase inhibitors as a new class of immunosuppressive drugs. Dr. O'Shea developed a Cooperative Research and Development Agreement with the pharmaceutical company Pfizer, which generated one such compound that is approved for the treatment of rheumatoid arthritis. 

Dr. O'Shea graduated Phi Beta Kappa from St. Lawrence University, Canton, NY, and received his medical degree from the University of Cincinnati. After completing his residency in internal medicine at the State University of New York Upstate Medical University, Syracuse, he received subspecialty training in allergy and immunology at NIH. He was appointed chief of the NIAMS Molecular Immunology and Inflammation Branch in 2002, and became scientific director of the NIAMS Intramural Research Program in 2005. Dr. O'Shea has been the recipient of numerous awards and is a Fellow of the American Association for the Advancement of Science.

For the Ross Prize, Dr. O'Shea was selected by an awards committee comprised of:

  • Christopher J. Czura, PhD, vice president, scientific affairs, and executive editor, Molecular Medicine, Feinstein Institute for Medical Research;
  • Betty Diamond, MD, head, Center for Autoimmune Diseases and Musculoskeletal Disorders, Feinstein Institute;
  • Peter K. Gregersen, MD, head, Laboratory of Genomics and Human Genetics, Feinstein Institute;
  • Göran K. Hansson, MD, PhD, professor of experimental cardiovascular research, Karolinska Institute, Sweden;
  • Klas Kärre, MD, PhD, professor of molecular immunology, Karolinska Institute; and
  • Kevin J. Tracey, MD, president, Feinstein Institute.

About Molecular Medicine
Molecular Medicine is an open access, international, peer-reviewed biomedical journal published by The Feinstein Institute for Medical Research. Molecular Medicine strives to understand normal body functioning and disease pathogenesis at the molecular level, which may allow researchers and physician-scientists to use that knowledge in the design of specific molecular tools for disease diagnosis, treatment, prognosis, and prevention. To learn more, go to www.molmed.org.

About The Feinstein Institute for Medical Research
Headquartered in Manhasset, NY, The Feinstein Institute for Medical Research is home to international scientific leaders in many areas including Parkinson's disease, Alzheimer's disease, psychiatric disorders, rheumatoid arthritis, lupus, sepsis, human genetics, pulmonary hypertension, leukemia, neuroimmunology, and medicinal chemistry. The Feinstein Institute, part of the North Shore-LIJ Health System, ranks in the top 6th percentile of all National Institutes of Health grants awarded to research centers. For more information, visit www.FeinsteinInstitute.org.

SOURCE The Feinstein Institute for Medical Research

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducte...
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
The time is ripe for high speed resilient software defined storage solutions with unlimited scalability. ISS has been working with the leading open source projects and developed a commercial high performance solution that is able to grow forever without performance limitations. In his session at Cloud Expo, Alex Gorbachev, President of Intelligent Systems Services Inc., shared foundation principles of Ceph architecture, as well as the design to deliver this storage to traditional SAN storage co...
The speed of software changes in growing and large scale rapid-paced DevOps environments presents a challenge for continuous testing. Many organizations struggle to get this right. Practices that work for small scale continuous testing may not be sufficient as the requirements grow. In his session at DevOps Summit, Marc Hornbeek, Sr. Solutions Architect of DevOps continuous test solutions at Spirent Communications, explained the best practices of continuous testing at high scale, which is rele...
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Learn how to solve the problem of keeping files in sync between multiple Docker containers. In his session at 16th Cloud Expo, Aaron Brongersma, Senior Infrastructure Engineer at Modulus, discussed using rsync, GlusterFS, EBS and Bit Torrent Sync. He broke down the tools that are needed to help create a seamless user experience. In the end, can we have an environment where we can easily move Docker containers, servers, and volumes without impacting our applications? He shared his results so yo...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at @ThingsExpo, James Kirkland, Red Hat's Chief Arch...
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
It is one thing to build single industrial IoT applications, but what will it take to build the Smart Cities and truly society-changing applications of the future? The technology won’t be the problem, it will be the number of parties that need to work together and be aligned in their motivation to succeed. In his session at @ThingsExpo, Jason Mondanaro, Director, Product Management at Metanga, discussed how you can plan to cooperate, partner, and form lasting all-star teams to change the world...
Public Cloud IaaS started its life in the developer and startup communities and has grown rapidly to a $20B+ industry, but it still pales in comparison to how much is spent worldwide on IT: $3.6 trillion. In fact, there are 8.6 million data centers worldwide, the reality is many small and medium sized business have server closets and colocation footprints filled with servers and storage gear. While on-premise environment virtualization may have peaked at 75%, the Public Cloud has lagged in adop...
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
How do you securely enable access to your applications in AWS without exposing any attack surfaces? The answer is usually very complicated because application environments morph over time in response to growing requirements from your employee base, your partners and your customers. In his session at @DevOpsSummit, Haseeb Budhani, CEO and Co-founder of Soha, shared five common approaches that DevOps teams follow to secure access to applications deployed in AWS, Azure, etc., and the friction an...
Digital Transformation is the ultimate goal of cloud computing and related initiatives. The phrase is certainly not a precise one, and as subject to hand-waving and distortion as any high-falutin' terminology in the world of information technology. Yet it is an excellent choice of words to describe what enterprise IT—and by extension, organizations in general—should be working to achieve. Digital Transformation means: handling all the data types being found and created in the organizat...